Setting the Standard for Peer‐Reviewed Published Studies on Regenerative Products in Aesthetic Medicine and Post‐Procedure Wound Care

作者
Michael H. Gold,Terrence Colin Keaney,Rebecca Fitzgerald
出处
期刊:Journal of Cosmetic Dermatology [Wiley]
卷期号:25 (5): e70877-e70877
标识
DOI:10.1111/jocd.70877
摘要

The aesthetics market has historically been characterized by minimal regulatory oversight, leading to a proliferation of products with inconsistent safety testing data. The field of regenerative aesthetics, in particular, is relatively new and rapidly emerging. While regenerative aesthetics appears to hold great promise, and indeed may well include many of the most important advancements in our field, the growing and seemingly overwhelming number of products available that claim regenerative capacity can make it daunting for providers and their clients to sort out fact from hype and choose treatments backed by strong scientifically sound peer-reviewed published evidence of their safe and effective use to achieve youthful, glowing skin and reduce post-procedure complications and downtime. In this context, two recent peer-reviewed published articles titled “Safety of Exogenous Recombinant Human Platelet-Derived Growth Factor-BB (rhPDGF-BB) for Medical and Cosmetic Applications: A Review” [1] and “Safety of up to 140 Daily Applications of Recombinant Human Platelet-Derived Growth Factor (rhPDGF-BB) onto Skin Wounds: Unboxing the Evidence” [2] are worthy of highlighting. These papers summarize an extensive portfolio of safety studies from both nonclinical models and randomized-controlled clinical trials that have established the strong safety profile for recombinant pure PDGF-BB manufactured and tested according to strict guidelines established by the Food and Drug Administration (FDA). The tens of thousands of study subjects, decades of follow-up, rigorous scientific methods and statistical analyses applied and summarized in these articles must be recognized by our field as the standard for all regenerative products in dermatology, plastic and reconstructive surgery, aesthetic medicine and wound care. Bioregenerative agents, like pure PDGF-BB, have become increasingly popular in aesthetics due to the natural improvement in skin quality, texture, firmness, and radiance over time, rather than the immediate and often temporary physical augmentation of tissue provided by fillers. Unlike the more artificial effects of early aesthetic treatments, bioregenerative products stimulate the body's own healing and regenerative mechanisms at the cellular level, promoting long-lasting structural and functional changes within the tissue, leading to sustained improvement over time and better results. However, it is important for health care providers to be aware that not all purported regenerative products in aesthetic medicine have undergone rigorous nonclinical and clinical pharmacokinetic and toxicology studies to establish the margin of safety, potential risks, and contraindications. Pure PDGF-BB presents a unique entry into aesthetic medicine compared to these other therapies. PDGF harnesses the body's innate healing power to regenerate and rejuvenate soft tissue and skin via stimulation of extracellular matrices such as collagen, elastin, and natural hyaluronic acid production and cellular renewal [3]. As the active pharmaceutical ingredient in four FDA-approved products to treat chronic skin wounds and regenerate soft tissues and bone, pure recombinant PDGF-BB research spans three decades and includes a robust portfolio of safety and pharmacology studies from standardized nonclinical models and long-term randomized clinical trials [4]. As summarized in the two articles cited above, safety studies on recombinant pure PDGF-BB include topical, injectable, and implantable routes of administration, across a wide range of doses—often thousands of times higher than we use in our field—and frequency—one time to weekly to daily applications—to establish the margin of safety and risks associated with its use [1]. Pharmacokinetic studies have demonstrated that exogenously applied PDGF-BB acts locally, with a short half-life and minimal systemic exposure even at very high doses in both animals and humans [5-7]. Skin irritation, hypersensitivity, and toxicity testing have revealed no significant adverse reactions to pure PDGF-BB delivery via subcutaneous, intramuscular, intradermal, intraperitoneal, or intravenous injections, repeated topical administration, or implanted combination devices across a range of doses in multiple animal models [8, 9]. Reproductive toxicity studies reported no treatment-related mortality or significant adverse effects in rats receiving daily IV injections of pure PDGF over 21 days of gestation [8, 9]. The clinical safety data for pure PDGF-BB is even more impressive. The role of exogenous pure PDGF in cancer biology has been extensively studied, debated, and eventually refuted when the FDA removed the boxed warning after long-term, retrospective, propensity-matched studies comparing over 13 000 patients treated with up to 140 daily applications of topical PDGF-BB or not treated with topical PDGF, and with over a decade of follow-up showed no increased risk of cancer incidence or cancer-related mortality with pure PDGF-BB treatment [2, 10, 11]. Moreover, safety outcomes from over 100 clinical trials spanning 25+ years and involving over 15 000 subjects showed similar rates of adverse events and complications between PDGF-treated and control groups in randomized-controlled, double-blinded clinical trials [4]. In summary, robust, scientifically sound safety data builds consumer trust in our field and gives providers confidence when making clinical decisions that will optimize patient outcomes. The extensive database of published studies on pure PDGF-BB stands out as exemplary, rigorous testing of a regenerative product. The rigorous safety evaluations performed and evidence-based data for pure PDGF-BB summarized in these peer-reviewed publications [1, 2] are a gift to our field and establish the standard that our profession should require for peer-reviewed published studies before widespread commercial adoption of future bioregenerative products. The authors declare no conflicts of interest. The data that support the findings of this study are available from the corresponding author upon reasonable request.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
zhanglinfeng完成签到,获得积分10
刚刚
littleE完成签到 ,获得积分10
刚刚
新帅完成签到,获得积分10
刚刚
Ambition完成签到,获得积分20
刚刚
Rhea完成签到,获得积分10
刚刚
鹰少完成签到,获得积分10
刚刚
活力的歪歪完成签到,获得积分10
1秒前
默默完成签到,获得积分10
1秒前
Poisomber完成签到,获得积分10
2秒前
王王王完成签到 ,获得积分10
3秒前
3秒前
史璐发布了新的文献求助10
3秒前
刘凯发布了新的文献求助10
3秒前
TQ完成签到,获得积分10
3秒前
bigpluto完成签到,获得积分10
3秒前
慕薯殿焚完成签到,获得积分10
3秒前
懒羊羊q完成签到,获得积分10
3秒前
健忘冷风完成签到,获得积分10
4秒前
墙墙完成签到,获得积分10
4秒前
冬可期完成签到 ,获得积分10
4秒前
hetao286完成签到,获得积分10
4秒前
4秒前
欣喜书兰完成签到 ,获得积分10
5秒前
小二郎的应助被Rony采纳,获得10
5秒前
NNi完成签到,获得积分10
5秒前
羊羊羊完成签到,获得积分10
5秒前
烟花的应助被HXuer采纳,获得10
6秒前
天羽纵梦完成签到,获得积分10
6秒前
Li完成签到,获得积分10
6秒前
6秒前
cg666完成签到 ,获得积分10
6秒前
6秒前
雪白煜城完成签到,获得积分10
6秒前
快乐画板完成签到,获得积分10
6秒前
栗子完成签到,获得积分10
7秒前
7秒前
星辰大海的应助被可爱的豆芽采纳,获得10
7秒前
molihuakai的应助被stone采纳,获得10
7秒前
真不爱学习完成签到 ,获得积分10
7秒前
rice完成签到,获得积分10
8秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1500
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
八旗制度の研究 600
Analyses de reconnaissances de dettes passées devant les échevins d'Ypres (1249-1291) 600
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8159288
求助须知:如何正确求助?哪些是违规求助? 9554702
关于积分的说明 21720900
捐赠科研通 7748911
什么是DOI,文献DOI怎么找? 3427184
关于科研通互助平台的介绍 2552111
邀请新用户注册赠送积分活动 2471479